Competing endogenous RNA regulation in hematologic malignancies

Clin Chim Acta. 2020 Oct:509:108-116. doi: 10.1016/j.cca.2020.05.045. Epub 2020 May 29.


The clinical application of cytogenetic analysis and molecular-targeted drugs has dramatically improved the prognosis for many patients with hematologic malignancy, especially for those with chronic myeloid leukemia (CML) and acute promyelocytic leukemia (APL). Nevertheless, the treatment of hematologic malignancies is still faced with problems, such as disease recurrence and drug resistance, so further exploring the underlying molecular mechanism is urgent. With the discovery of different RNA species, the mechanism of RNA-RNA interaction has caught more and more attention. "Competing endogenous RNA (ceRNA) hypothesis" is one of the fascinating products of recent researches. CeRNAs are endogenous RNA transcripts that share mutual microRNA response elements (MREs) and regulate expression of each other by competing for the same microRNAs pools. The hypothesis links different RNA species together and enriches our understanding of the human genome. Here, we introduce the hypothesis critically, summary the research progress in the field of hematologic malignancies and the current investigation methods, and address its promising clinical value in offering new predictive, prognostic biomarkers and therapeutic targets.

Keywords: Clinical significance; Competing endogenous RNA; Hematologic neoplasms; Methods; Physiopathology.

Publication types

  • Review

MeSH terms

  • Gene Expression Regulation, Neoplastic
  • Hematologic Neoplasms* / genetics
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Leukemia, Promyelocytic, Acute*
  • MicroRNAs* / genetics
  • RNA
  • RNA, Long Noncoding*


  • MicroRNAs
  • RNA, Long Noncoding
  • RNA